Donanemab, which will be marketed as Kisunla, will compete with Biogen and Eisai’s Leqembi.
Tag Archive for: Eisai
Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.
The companies have launched their Alzheimer’s treatment Leqembi in China, the third country after the United States and Japan.
After missing their initial target in March 2024, Eisai and Biogen have initiated a rolling BLA for a subcutaneous maintenance formulation of Leqembi, which could offer a more convenient dosing schedule for Alzheimer’s disease patients.
Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell.
The filing of a Biologics License Application for a subcutaneous version of Biogen and Eisai’s Leqembi (lecanemab) has been delayed due to procedural reasons, the companies announced Monday.
The European Union’s medicines regulator has delayed it decision on Eisai and partner Biogen’s Alzheimer’s disease drug that was expected this week, the Japanese company said today.
The company expects to reach 90% of its target for integrated delivery networks (IDNs) used to administer the drug in the U.S. in the fiscal year ending this month, its CEO stated.
During yesterday’s third-quarter fiscal year 2023 earnings report, Eisai revealed that the launch of its Biogen-partnered Alzheimer’s disease treatment Leqembi (lecanemab) has not been going according to plan, making the company’s goal of treating 10,000 patients by the end of March 2024 appear out of reach.
The two companies are preparing to launch the drug in the second quarter of Eisai’s 2024/25 business year starting in April.